Using injectable platelet-rich fibrin with bovine bone grafts to treat intrabony periodontal defects
Evaluation of the Effect of Injectable Platelet-Rich Fibrin in the Treatment of Periodontal Intrabony Defects With Xenogenic Grafts: a Randomized Controlled Clinical Trial
This will try adding injectable platelet-rich fibrin (i-PRF) to bovine bone grafts to see if adults with stage III periodontitis and intrabony defects heal better than with grafts alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 16 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Saglik Bilimleri Universitesi Academic / other |
| Locations | 1 site (Istanbul, Üsküdar) |
| Trial ID | NCT07146776 on ClinicalTrials.gov |
What this trial studies
Adults with stage III periodontitis and interproximal intrabony defects will undergo open flap debridement and receive either bovine-derived xenogenic bone graft mixed with i-PRF or the same graft mixed with saline. Clinical measures (for example probing pocket depth and defect area) and radiographic bone fill will be recorded and compared between the two groups. The aim is to determine whether i-PRF increases bone fill and reduces defect size versus graft alone. Findings will show whether adding this tissue-friendly biologic improves commonly used bovine xenograft outcomes for intrabony defects.
Who should consider this trial
Good fit: Adults aged 18–65 with stage III periodontitis who have interproximal 2- or 3-walled intrabony defects ≥3 mm and persistent probing depths ≥5 mm after initial therapy, and who are non-smokers or light smokers (≤10 cigarettes/day).
Not a fit: People with single-walled defects, uncontrolled systemic disease (such as uncontrolled diabetes), heavy smokers, those recently on antibiotics or with recent periodontal surgery, and pregnant or breastfeeding patients are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, adding i-PRF could increase bone fill and reduce pocket depths and defect size, improving periodontal healing after surgery.
How similar studies have performed: Previous studies combining PRF derivatives with various graft materials have shown promising results, but the specific combination of i-PRF with bovine-derived xenograft for intrabony defects has not been studied before.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female patients aged 18-65 years * Patients with Stage III Periodontitis according to the AAP-EFP 2017 Periodontal Disease Classification * PPD≥5 mm (if persistent 6 weeks after initial periodontal treatment) * Intrabony defects in the interproximal region with 2 or 3 walls and a depth of at least ≥3 mm * Non-smokers (those who smoke up to 10 per day may be included) Exclusion Criteria: * Patients under 18 years of age or older than 65 years of age * Patients unable to consent * Systemic diseases that could affect the success of surgery, such as uncontrolled diabetes * Single-walled intrabony defects * Those who have taken antibiotics, anti-inflammatory or immunosuppressive drugs, or birth control pills within the three months prior to the study * Those who have received active periodontal treatment within the last six months and periodontal surgery within the last year * Smoking more than 10 cigarettes per day * Pregnancy or breastfeeding * Those taking medications that affect the gums (e.g., calcium channel blockers, phenytoin or cyclosporine) * Teeth with furcation defects * Those undergoing active orthodontic treatment * Those who are allergic to the biomaterials used in the study or prescribed medications
Where this trial is running
Istanbul, Üsküdar
- Sağlık Bilimleri Üniversitesi — Istanbul, Üsküdar, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Tuğçe Paksoy, Associate Professor
- Email: tugceakap86@hotmai.com
- Phone: +905534490452
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.